October 23, 2020 — Johnson & Johnson announced today that
Anti-Influenza Drug Avigan® Tablet Meets Primary Endpoint in Phase III Clinical Trial in Japan for COVID-19 Patients
TOKYO — September 23, 2020 FUJIFILM Toyama Chemical Co., Ltd.
Africa struggles to stem deadly flood of fake medicine
After he was struck down by malaria and typhoid, Togolese
Melatonin for jet lag shouldn’t be available on NHS concludes expert review
Patients shouldn’t be prescribed melatonin for jet lag on the
Luspatercept mitigates anemia in lower-risk myelodysplastic syndromes
For patients with lower-risk myelodysplastic syndromes with ring sideroblasts who
FDA documents analysis reveals inadequate monitoring of safe opioid use program
A risk-management program set up in 2012 by the U.S.
Flu antiviral has bigger benefits for sicker, older patients
A Europe-wide study conducted over three flu seasons finds that
Snake venom study reveals troubling shortcomings in antivenom therapy in India
Commercially available antivenoms in India can be ineffective in treating
Bladder cancer treatment rejected for routine use on NHS in England
An immunotherapy treatment for some people with bladder cancer, currently available
Doctors should avoid co-prescribing benzodiazepines to opioid dependent patients
Doctors should avoid co-prescribing benzodiazepines to opioid dependent patients who